secwatch.observer — SEC 8-K summary
======================================

Issuer:     RetinalGenix Technologies Inc. (RTGN)
CIK:        0001836295
Form:       8-K
Filed at:   2021-12-30T23:59:59+00:00
Accession:  0001493152-21-032831
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RetinalGenix exchanges 28M shares for pre-funded warrant; outstanding shares drop to 14.2M
--------------------------------------------------------------------------------

- Exchanged 28,014,540 shares held by Sanovas Ophth for a pre-funded warrant to purchase same number of shares at $0.0001 per share.
- Outstanding shares reduced from ~42.2M to 14,166,114 after cancellation of exchanged shares.
- Transaction with related party: CEO Jerry Katzman is sole manager of Sanovas Ophth.
- Warrant is immediately exercisable and terminates when exercised in full; no new cash received.
- Issued under Section 3(a)(9) exemption; no additional consideration was paid.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1836295/000149315221032831/0001493152-21-032831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1836295/000149315221032831/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-032831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer